{"filings":[{"id":805841,"accession_number":"0001193125-26-253478","cik":1806310,"company_name":"Taysha Gene Therapies, Inc.","ticker":"TSHA","form_type":"8-K","filed_at":"2026-06-02T20:05:28+00:00","items":["5.07"],"status":"ready","headline":"Taysha Gene Therapies annual meeting elects directors, ratifies auditor, approves say-on-pay","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Shareholders elected Sean P. Nolan (169.1M for) and Laura Sepp-Lorenzino (150.1M for) as directors until 2029.","Deloitte & Touche ratified as independent auditor for FY2026 with 243.8M votes for.","Non-binding advisory vote on named executive officer compensation approved: 168.1M for vs 36.4M against.","Advisory vote on frequency of say-on-pay: annual basis chosen with 203.8M votes for one year.","Approximately 84.86% of outstanding shares were represented at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":1685372399.64,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95619,"accession_number":"0001193125-26-207633","cik":1806310,"company_name":"Taysha Gene Therapies, Inc.","ticker":"TSHA","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Taysha Q1 net loss $42.4M; FDA aligns on TSHA-102 BLA submission pathway","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $42.4M ($0.12/sh) vs $21.5M ($0.08/sh) Q1 2025; R&D expense doubled to $33.8M on PPQ and clinical costs.","Cash $276.6M; company expects runway into 2028.","FDA reaffirmed alignment on TSHA-102 BLA pathway including pivotal trial design, endpoints, and potential 6-month interim submission.","Dosing in REVEAL pivotal and ASPIRE trials on track for Q2 2026 completion; no treatment-related SAEs or DLTs to date.","BLA-enabling PPQ campaign initiated April 2026; completion expected Q4 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1685372399.64,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108812,"accession_number":"0001193125-26-115177","cik":1806310,"company_name":"Taysha Gene Therapies, Inc.","ticker":"TSHA","form_type":"8-K","filed_at":"2026-03-19T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Taysha reports FY2025 net loss $109M; TSHA-102 pivotal trial dosing on track to complete Q2 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $109.0M ($0.34/share) vs $89.3M ($0.36) in 2024; R&D expenses rose to $86.4M.","Cash $319.8M as of Dec 31, 2025; raised $50M via ATM in Q4; expects funding into 2028.","Dosed multiple Rett patients in REVEAL pivotal trial; enrollment advancing, on track to complete dosing in Q2 2026.","FDA cleared ASPIRE trial in patients aged 2 to <4 yrs; alignment on CMC and data pooling for BLA submission.","TSHA-102 generally well tolerated; no treatment-related SAEs or DLTs as of March 2026 data cutoff."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1685372399.64,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125260,"accession_number":"0001193125-25-263543","cik":1806310,"company_name":"Taysha Gene Therapies, Inc.","ticker":"TSHA","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["1.01","2.02","9.01"],"status":"ready","headline":"Taysha Gene Therapies: TSHA-102 gets FDA Breakthrough Therapy, Q3 net loss $32.7M","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA granted Breakthrough Therapy designation for TSHA-102 in Rett syndrome; FDA alignment finalized on REVEAL pivotal trial protocol with 6-month interim analysis to expedite BLA.","First patient dosing in REVEAL pivotal trial scheduled Q4 2025; enrollment to continue at multiple sites.","Regained full unencumbered rights to TSHA-102 after Astellas option agreement expired in October 2025.","Q3 2025 net loss $32.7M ($0.09/share); R&D $25.7M; cash $297.3M expected to fund operations into 2028.","David McNinch appointed Chief Commercial Officer in September 2025; TSHA-102 generally well tolerated with no treatment-related SAEs in 12 patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1685372399.64,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125259,"accession_number":"0001193125-25-241415","cik":1806310,"company_name":"Taysha Gene Therapies, Inc.","ticker":"TSHA","form_type":"8-K","filed_at":"2025-10-16T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Taysha regains full rights to TSHA-102 for Rett syndrome after Astellas option expires","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Regained full rights to lead TSHA-102 program after 2022 Option Agreement with Astellas expired.","TSHA-102 has FDA Breakthrough Therapy designation; Part A REVEAL data showed 100% response rate on primary endpoint.","REVEAL pivotal trial dosing of first patient scheduled this quarter; FDA alignment on protocol and SAP obtained.","Unencumbered rights enable full strategic flexibility and optionality for Taysha."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1685372399.64,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125258,"accession_number":"0001193125-25-235212","cik":1806310,"company_name":"Taysha Gene Therapies, Inc.","ticker":"TSHA","form_type":"8-K","filed_at":"2025-10-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Taysha reports 100% milestone response in Phase 1/2 REVEAL Part A for TSHA-102; 165 additional functional gains","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 10 patients (Part A) achieved ≥1 natural-history-defined developmental milestone post-TSHA-102, 0% to <6.7% likelihood without treatment.","22 developmental milestones gained across domains of communication, fine motor, gross motor.","Supplemental analysis: 165 additional skills/improvements across all 10 patients from structured scales (MSEL-A, R-MBA, ORCA).","Data presented at 54th CNS Annual Meeting; reinforces broad, multi-domain impact on activities of daily living.","Study evaluates high dose (1x10^15 vg) and low dose (5.7x10^14 vg) in females aged 6-21 years with Rett syndrome."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1685372399.64,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125257,"accession_number":"0001193125-25-227505","cik":1806310,"company_name":"Taysha Gene Therapies, Inc.","ticker":"TSHA","form_type":"8-K","filed_at":"2025-10-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA grants Breakthrough Therapy designation for TSHA-102 in Rett syndrome; pivotal trial protocol finalized","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA Breakthrough Therapy designation for TSHA-102 based on Part A data from 12 patients showing 100% response rate on milestone gain.","FDA alignment finalized on REVEAL pivotal trial protocol and SAP; 6-month interim analysis could expedite BLA by at least two quarters.","Pivotal trial to enroll 15 females aged 6-22 with primary endpoint of milestone gain; enrollment on track for Q4 2025.","Clinical data also showed dose-dependent improvements on R-MBA and CGI-I; safety generally well-tolerated."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1685372399.64,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141991,"accession_number":"0001193125-25-178504","cik":1806310,"company_name":"Taysha Gene Therapies, Inc.","ticker":"TSHA","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Taysha Q2 net loss $26.9M; TSHA-102 pivotal trial site activation begun, enrollment Q4 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $312.8M after $230M follow-on offering; runway extended into 2028.","Net loss $26.9M ($0.09/share) vs $20.9M ($0.09) in Q2 2024.","REVEAL pivotal trial site activation commenced; FDA and Health Canada feedback received.","100% response rate on primary endpoint in Part A; no treatment-related SAEs or DLTs in 12 patients.","New supplemental clinical data from Part A expected in Q4 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":4288000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1685372399.64,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159941,"accession_number":"0001193125-25-133745","cik":1806310,"company_name":"Taysha Gene Therapies, Inc.","ticker":"TSHA","form_type":"8-K","filed_at":"2025-06-03T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Taysha Gene Therapies shareholders approve authorized share increase to 700M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Authorized common stock increased from 400M to 700M shares; approved 171.3M for, 8.2M against.","Directors Phillip B. Donenberg and Sukumar Nagendran elected with 114.3M and 123.3M votes for, respectively.","Deloitte & Touche ratified as independent auditor for FY2025; 179.4M votes for.","Annual meeting turnout: 179.6M shares (~87%) of 205.1M outstanding represented."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":1685372399.64,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159940,"accession_number":"0001193125-25-130709","cik":1806310,"company_name":"Taysha Gene Therapies, Inc.","ticker":"TSHA","form_type":"8-K","filed_at":"2025-05-29T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Taysha prices $187M stock offering; TSHA-102 achieves 100% milestone gain, FDA agrees on pivotal trial design","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 46.9M shares at $2.75/sh and 25.9M pre-funded warrants at $2.749; net proceeds ~$187.4M.","Underwriters granted 30-day option for up to 10.9M additional shares; closing expected May 30.","TSHA-102 in Rett syndrome: 100% (10/10) patients gained/regained ≥1 milestone post-treatment, with high dose outperforming low dose.","FDA provided written alignment on single-arm pivotal Part B trial design; primary endpoint: developmental milestone gain/regain in patients ≥6 yrs.","Astellas option to license TSHA-102 remains exercisable 90 days after receipt of Rett Data Package expected mid-2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1685372399.64,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159937,"accession_number":"0001193125-25-129849","cik":1806310,"company_name":"Taysha Gene Therapies, Inc.","ticker":"TSHA","form_type":"8-K/A","filed_at":"2025-05-29T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Taysha reports FDA-aligned pivotal trial for TSHA-102; 100% of Part A patients gained milestones","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FDA aligned on single-arm pivotal Part B trial (N=15) for TSHA-102 in Rett syndrome patients ≥6 years; primary endpoint: developmental milestone gain/regain.","Part A: 100% (10/10) of patients aged 6-21 gained ≥1 milestone; high dose showed faster and deeper effects vs low dose.","Natural history data (~1,100 patients) showed ~0% likelihood of milestone gain/regain after age 6, supporting trial design.","No treatment-related SAEs or DLTs; all related AEs mild-to-moderate across 12 patients.","Company suspended $100M ATM prospectus; Sales Agreement remains in effect; new prospectus required for future sales."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1685372399.64,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159939,"accession_number":"0001193125-25-129494","cik":1806310,"company_name":"Taysha Gene Therapies, Inc.","ticker":"TSHA","form_type":"8-K","filed_at":"2025-05-28T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Taysha Gene Therapies Announces FDA Alignment on Pivotal Part B Trial Design for TSHA-102 in Rett Syndrome","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["100% of 10 patients in Part A gained/regained ≥1 developmental milestone post-TSHA-102, with ~0% likelihood from natural history data.","FDA supports single-arm open-label pivotal trial (N=15) with primary endpoint of developmental milestone gain/regain in patients ≥6 years.","High dose outperformed low dose, with dose-dependent effects deepening over time; no treatment-related SAEs or DLTs.","Analysis of IRSF natural history study (N~1100) showed patients ≥6 years in developmental plateau, <6.7% likelihood of milestone gain.","Company expects to submit protocol this quarter and initiate pivotal trial in Q3 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":1685372399.64,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159938,"accession_number":"0001193125-25-120329","cik":1806310,"company_name":"Taysha Gene Therapies, Inc.","ticker":"TSHA","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Taysha secures FDA alignment on TSHA-102 pivotal trial design; Q1 net loss $21.5M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FDA alignment on pivotal Part B trial design; IND amendment with protocol/SAP expected Q2 2025, potentially expediting registration.","TSHA-102 well tolerated: no treatment-related SAEs or DLTs in 10 patients (6 high dose, 4 low dose) as of April 10, 2025 cutoff.","Q1 2025 net loss $21.5M ($0.08/sh) vs $24.1M ($0.10/sh) in Q1 2024; cash $116.6M expected into Q4 2026.","R&D expenses $15.6M, down from $20.7M YoY due to lower manufacturing costs; G&A expenses $8.2M, up from $7.1M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1685372399.64,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178279,"accession_number":"0001193125-25-035882","cik":1806310,"company_name":"Taysha Gene Therapies, Inc.","ticker":"TSHA","form_type":"8-K","filed_at":"2025-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Taysha reports FY2024 net loss $89.3M; TSHA-102 well tolerated in all 10 patients across REVEAL trials","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $89.3M ($0.36/sh) vs $111.6M ($0.96/sh) in FY2023; cash $139.0M, runway into Q4 2026.","TSHA-102 (Rett syndrome) no treatment-related SAEs or DLTs in all 10 patients (6 high dose, 4 low dose) as of Feb 17, 2025 cutoff.","Dosing of Part A in both REVEAL Phase 1/2 trials completed; pivotal trial design update expected H1 2025.","R&D expenses $66.0M (up $9.2M YoY) driven by GMP manufacturing and clinical activities; G&A $29.0M (down $1.0M).","Safety and efficacy data from high-dose cohorts (n=3 each) and low-dose updates expected H1 2025 for both adolescent/adult and pediatric trials."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.36,"consensus_revenue_estimate":null,"consensus_revenue_actual":8333000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1685372399.64,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194927,"accession_number":"0001193125-24-257205","cik":1806310,"company_name":"Taysha Gene Therapies, Inc.","ticker":"TSHA","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Taysha Q3 net loss $25.5M; TSHA-102 high dose safe; FDA aligns on pivotal trial design","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $25.5M ($0.10/sh) vs $117.1M loss in Q3 2023; cash $157.7M into Q4 2026.","High dose TSHA-102 well tolerated; no SAEs or DLTs in 2 adolescent/adult and 1 pediatric patient.","FDA aligned on trial design, endpoints, and natural history dataset for Part B of REVEAL trials.","FDA approved pivotal TSHA-102 product manufactured with final commercial manufacturing process for REVEAL trials.","Safety and efficacy data from high dose cohorts of both REVEAL trials expected H1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.29,"consensus_revenue_estimate":null,"consensus_revenue_actual":6311000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1685372399.64,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211221,"accession_number":"0001193125-24-198392","cik":1806310,"company_name":"Taysha Gene Therapies, Inc.","ticker":"TSHA","form_type":"8-K","filed_at":"2024-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Taysha reports Q2 net loss $20.9M, cash $172.7M; TSHA-102 high dose data in 1H 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss narrowed to $20.9M ($0.09/share) from $24.6M ($0.38/share) in Q2 2023.","Cash $172.7M at June 30; runway extended into Q4 2026 after $76.8M public offering.","TSHA-102 low dose data showed durable improvements and no SAEs/DLTs in adult and pediatric trials.","High dose cohort dosing started; safety/efficacy data from both REVEAL trials expected 1H 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":4523000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1685372399.64,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229773,"accession_number":"0001193125-24-169191","cik":1806310,"company_name":"Taysha Gene Therapies, Inc.","ticker":"TSHA","form_type":"8-K","filed_at":"2024-06-26T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Taysha Gene Therapies prices $75M public offering of common stock and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$75M; 14,361,113 shares at $2.25 each and 18,972,221 pre-funded warrants at $2.249 each.","Net proceeds ~$70M (~$80.6M if underwriters exercise option for 5M additional shares).","Cash runway extended into Q4 2026; proceeds fund operating expenses and capex.","Pre-funded warrants exercisable at $0.001 per share with 4.99%/9.99% ownership caps.","Jefferies, Goldman Sachs, and Cantor act as book-running managers; closing expected June 27, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1685372399.64,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229772,"accession_number":"0001193125-24-168479","cik":1806310,"company_name":"Taysha Gene Therapies, Inc.","ticker":"TSHA","form_type":"8-K","filed_at":"2024-06-26T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Taysha launches $75M public offering; reports positive clinical data in Rett syndrome","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Commenced underwritten public offering of up to $75M in common stock and pre-funded warrants; underwriters have 30-day option for additional 15%.","TSHA-102 in Rett syndrome shows sustained improvements in motor, hand function, and seizure reduction in two adult patients at 52 and 36 weeks.","IDMC approved dose escalation to cohort 2; first high-dose patient dosed in Q2 2024; initial data from cohort 2 expected H2 2024.","Received RMAT designation from FDA for TSHA-102 in April 2024, providing expedited development pathway."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1685372399.64,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229771,"accession_number":"0001193125-24-163050","cik":1806310,"company_name":"Taysha Gene Therapies, Inc.","ticker":"TSHA","form_type":"8-K","filed_at":"2024-06-18T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Taysha Gene Therapies announces positive TSHA-102 clinical data; IDMC approves early advancement to high dose cohort","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Longer-term adult data (up to 52 weeks) show durable improvements in motor, communication, autonomic, and seizure domains.","Adult patient 1 gained ability to sit unassisted for first time in over a decade; patient 2 seizure-free for 8.5 months at 25% lower anti-seizure medication.","Initial pediatric data (up to 22 weeks) show early developmental gains: improved hand function, gait, and communication via eye-gaze device.","IDMC approved early advancement to high dose cohort in pediatric trial; dosing expected Q3 2024 after review of adult high dose safety.","TSHA-102 generally well-tolerated with no drug-related serious adverse events or dose-limiting toxicities in either trial."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1685372399.64,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229770,"accession_number":"0001193125-24-150323","cik":1806310,"company_name":"Taysha Gene Therapies, Inc.","ticker":"TSHA","form_type":"8-K","filed_at":"2024-05-30T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Taysha Gene Therapies holds 2024 annual meeting; directors elected and auditor ratified","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Shareholders elect Sean Stalfort and Alison Long as directors until 2027.","Deloitte & Touche LLP ratified as independent auditor for FY2024.","Approximately 80% of outstanding shares (149.6M of 187M) were represented at the meeting.","Director votes: Stalfort 131.8M for, 287.6K withheld; Long 132.0M for, 77.5K withheld.","Auditor ratification: 149.5M for, 60.4K against, 100.5K abstained; no broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":1685372399.64,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229769,"accession_number":"0001193125-24-138253","cik":1806310,"company_name":"Taysha Gene Therapies, Inc.","ticker":"TSHA","form_type":"8-K","filed_at":"2024-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Taysha Q1 net loss $24.1M; TSHA-102 advances to high-dose cohort, gets RMAT designation","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 net loss of $24.1M ($0.10/share) vs $17.6M loss a year ago; R&D expenses $20.7M.","FDA granted RMAT designation for TSHA-102 for Rett syndrome based on early safety/efficacy data.","Completed low-dose cohort in REVEAL adult trial; enrolled first patient in high-dose (1x10^15 vg) for Q2 dosing.","Second pediatric patient dosed in low-dose cohort; initial data from both trials expected mid-2024.","Cash $124M; expects to fund operations into 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":3411000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1685372399.64,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248264,"accession_number":"0001193125-24-071321","cik":1806310,"company_name":"Taysha Gene Therapies, Inc.","ticker":"TSHA","form_type":"8-K","filed_at":"2024-03-19T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Taysha reports 2023 net loss of $111.6M; TSHA-102 shows sustained improvements in Rett patients","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $15.5M for full-year 2023 (up from $2.5M in 2022) from Astellas option agreement.","Net loss of $111.6M ($0.96 loss per basic share) vs. $166.0M ($3.78/share) in 2022; includes $34.5M non-cash warrant expense.","Cash and equivalents of $143.9M as of Dec 31, 2023; cash runway expected into 2026.","TSHA-102 low dose (5.7x10^14 vg) in REVEAL adult trial: well-tolerated, no SAEs; patient 1 shows improved sitting, sleep, social interaction at week 35; patient 2 shows reduced seizures at week 19.","IDMC approved early dose escalation to high dose (1x10^15 vg) in adult/pediatric trials; initial pediatric low-dose data due mid-2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1685372399.64,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}